SOURCE: ONE Bio, Corp.

February 11, 2010 08:30 ET

ONE Bio Expands Distributors on New Product Launch

New Product Expected to Deliver $8 Million in Revenue in 2010

MIAMI, FL--(Marketwire - February 11, 2010) - ONE Bio, Corp. ("ONE" or the "Company") (OTCBB: ONBI), an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, announced the addition of 8 new distributors to support the launch of the Company's Jinglao "King of Medicine" brand beverage crystals from Ganoderma Lucidum extracts.

Extracts from Ganoderma Lucidum are believed by Chinese medical professionals to be a valuable remedy for weight management, immunity boost, tumor prevention and to act as powerful antioxidants. Several books, including the one written by Dr. Shi-Jean Lee, a renowned Chinese medical professional, discuss the benefits associated with the long term use of Ganoderma Lucidum extracts.

"We have seen strong demand for our Jinglao brand since our launch. We sold over $300k in our first month and anticipate 2010 sales for Jinglao to reach in excess of $8 million. We strongly believe that the increase in the number of products in our over-the-counter portfolio will result in strong organic growth this year," stated ONE's CEO Marius Silvasan. "Over-the-counter health products are a lucrative segment in the marketplace. We believe that our focus on the development of these highly demanded and profitable products will contribute to our future success," added Mr. Silvasan.

"To support distribution for Jinglao we added 8 new regional distributors in key markets along the east coast of China," stated ONE's China President Min Zhao. "We also see strong demand for Jinglao outside of China including the United States and other Asian countries. We intend to expand our distribution in those areas later this year," added Mr. Zhao.

About ONE Bio, Corp.

ONE Bio, Corp. ("ONE") (OTCBB: ONBI) (www.onehcorp.com), headquartered in Miami, FL, is an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural supplements and organic products. ONE is focused on the Asia Pacific region. Key products include widely recognized Solanesol, CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic bamboo health food and beverages. ONE's growth plan targets an aggressive acquisition driven strategy supported by strong organic growth. Through ONE, small private companies gain access to capital, experienced management and strategic insight. ONE builds strong synergies amongst all subsidiaries to enhance shareholder value. ONE is working with each subsidiary to promote organic and acquisition driven growth.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). ONE Bio, Corp. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and ONE Bio, Corp. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Contact Information